UCB, a global biopharmaceutical company, announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) st...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
Centivax, a biotechnology company that develops broad-spectrum vaccines to combat rapidly evolving pathogens, has announced a strategic collaboration with ...
Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...
Arvinas, Inc. announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulves...
HealthTree Foundation, a global nonprofit dedicated to improving outcomes for blood cancer patients through technology-driven solutions, announces the laun...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced new findings from the SLIM LIVER study (also known as A5371)...
CervoMed Inc. a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), announced positive ...
To gain a competitive edge, the company partnered with DelveInsight to analyze competitor launch timelines, first-to-market companies, ...
Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimila...
Bristol Myers Squibb announced positive data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of ...
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, and Tiefenbacher Group, a leading healthcare company...
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced the first patient has been dosed in the co...
Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...
© 2025 Biopharma Boardroom. All Rights Reserved.
